Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM for Ferroptosis Research

Executive Summary: Liproxstatin-1 is a potent and selective inhibitor of ferroptosis, exhibiting an IC50 of 22 nM in cellular assays, specifically blocking iron-dependent lipid peroxidation (APExBIO). Its mechanism centers on prevention of lipid peroxide accumulation, particularly effective in glutathione peroxidase 4 (GPX4)-deficient models (Yu et al., 2026). Liproxstatin-1 demonstrates in vivo efficacy by protecting renal and hepatic tissues from ferroptotic injury. For research workflows, it is soluble in DMSO and ethanol but insoluble in water, and requires cold storage at -20°C for stability. The product is distributed by APExBIO (SKU: B4987) and is a reference standard for ferroptosis pathway investigation.

Biological Rationale

Ferroptosis is a regulated cell death modality that depends on iron and is characterized by the accumulation of lipid peroxides within cellular membranes (Yu et al., 2026). The process is distinct from apoptosis, necroptosis, and cuproptosis, and plays a crucial role in physiological and pathological contexts, including tissue injury and cancer progression. GPX4 is a key enzyme that reduces lipid peroxides to non-toxic lipid alcohols, thereby preventing ferroptotic cell death. Inhibition or genetic depletion of GPX4 sensitizes cells to ferroptosis, and models lacking GPX4 are standard for evaluating ferroptosis inhibitors (see related article; this article updates mechanistic details and product handling parameters compared to the linked resource).

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 acts by blocking the accumulation of lipid peroxides, thereby preventing execution of ferroptosis. It exhibits high selectivity for ferroptosis over other regulated cell death pathways, such as apoptosis or pyroptosis. Mechanistically, Liproxstatin-1 interrupts the lipid peroxidation chain reaction induced by iron-dependent Fenton chemistry, acting downstream of GPX4 loss (Yu et al., 2026). In vitro, Liproxstatin-1 provides cytoprotection in the presence of ferroptosis inducers like RSL3 and erastin, particularly in GPX4-deficient cellular models. Its action is not mediated by direct iron chelation or radical scavenging, but rather by intercepting lipid peroxyl radicals within membranes (extended discussion; this article specifies lipid-phase targeting and in vivo benchmarks not detailed in the source linked here).

Evidence & Benchmarks

• Liproxstatin-1 inhibits ferroptosis in cellular assays with an IC50 of approximately 22 nM (https://www.apexbt.com/liproxstatin-1.html).
• It protects GPX4-deficient mouse embryonic fibroblasts from RSL3-induced death at nanomolar concentrations (https://doi.org/10.1016/j.ejmech.2025.118257).
• In vivo, Liproxstatin-1 prolongs survival in mice with kidney-specific Gpx4 deletion (https://www.apexbt.com/liproxstatin-1.html).
• The compound significantly reduces hepatic tissue damage in mouse models of ischemia/reperfusion injury (https://cy7-nhs-ester.com/index.php?g=Wap&m=Article&a=detail&id=766); this article integrates recent in vivo hepatic data not present in the linked review.
• Liproxstatin-1 is insoluble in water, but dissolves at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol with gentle warming and sonication (https://www.apexbt.com/liproxstatin-1.html).
• Stability is optimized by storage at -20°C, with prepared solutions recommended for short-term experimental use (https://www.apexbt.com/liproxstatin-1.html).
• It does not inhibit apoptosis, necroptosis, or cuproptosis at concentrations effective for ferroptosis inhibition (https://doi.org/10.1016/j.ejmech.2025.118257).

Applications, Limits & Misconceptions

Liproxstatin-1 is widely used to dissect ferroptosis-specific signaling pathways and to distinguish iron-dependent cell death from other forms. Its efficacy in GPX4-deficient and tissue injury models supports its use in studies of renal failure, hepatic ischemia/reperfusion, and emerging oncology indications (related article; this article further clarifies operational parameters and data reproducibility compared to the mechanistic overview provided in the source).

Common Pitfalls or Misconceptions

• Liproxstatin-1 will not inhibit cell death pathways unrelated to ferroptosis, including apoptosis, necroptosis, or cuproptosis.
• The compound is not an iron chelator or direct antioxidant; its effect is specific to lipid peroxidation chain inhibition.
• Insolubility in water can cause dosing errors; always dissolve in DMSO or ethanol per manufacturer instructions.
• Long-term storage in solution at room temperature leads to compound degradation and reduced potency.
• Its efficacy in non-mammalian or non-GPX4-dependent systems remains unproven.

Workflow Integration & Parameters

Liproxstatin-1 is available from APExBIO (SKU: B4987) as a high-purity powder. For experimental use, dissolve in DMSO (≥10.5 mg/mL) or ethanol (≥2.39 mg/mL) with gentle warming and sonication. Store stock solutions at -20°C and use within a few days for optimal activity. Recommended working concentrations in cell culture range from 10–100 nM, with titration advised for each model system. Liproxstatin-1 should be added prior to or concurrent with ferroptosis inducers for maximal protective effect. For in vivo studies, refer to published dosing protocols and monitor for solubility and stability constraints. For further workflow guidance, see this related resource; this article provides updated storage and dosing specifics, extending beyond the broader translational discussion in the linked article.

Conclusion & Outlook

Liproxstatin-1 stands as a benchmark ferroptosis inhibitor for academic and translational research. Its nanomolar potency, selectivity, and defined mechanism of action make it an essential tool for dissecting the iron-dependent lipid peroxidation pathway. As the field advances to explore ferroptosis in disease and therapy, Liproxstatin-1 will remain integral for experimental validation and mechanistic studies. Practitioners are advised to follow product-specific handling recommendations to ensure reproducible results (APExBIO).